Consensus conference on high-dose therapy with hematopoietic stem cell transplantation in diffuse large-cell lymphoma. Type of cells, optimal mobilization of stem cells--positive and negative selection.
Stem cell transplantation has played a role in the management of diffuse large-cell lymphoma for decades. The optimal source of the stem cells and the proper composition of the cellular graft product has not been defined. The field is changing rapidly and the future is likely to hold improvements and requirements that will further benefit the patient!
Kessinger
A
A
Section of Oncology/Hematology, University of Nebraska Medical Center, Omaha, USA. makessin@mail.unmc.edu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001781:Blood Component Removal; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D005312:Fetal Blood / Q000166:cytology; D016298:Hematopoietic Cell Growth Factors / Q000494:pharmacology / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000628:therapy*; D012641:Selection, Genetic; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D016298:Hematopoietic Cell Growth Factors